[
  {
    "ts": null,
    "headline": "Novavax slides after RFK Jr. casts doubts about COVID vaccine",
    "summary": "Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine’s single-antigen composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit",
    "url": "https://finnhub.io/api/news?id=9b6d2893f2c9dde9ea83a37f9f799ebc6249324346fe177915277c3aa29ae0f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744384814,
      "headline": "Novavax slides after RFK Jr. casts doubts about COVID vaccine",
      "id": 133880835,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine’s single-antigen composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit",
      "url": "https://finnhub.io/api/news?id=9b6d2893f2c9dde9ea83a37f9f799ebc6249324346fe177915277c3aa29ae0f0"
    }
  },
  {
    "ts": null,
    "headline": "Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer",
    "summary": "Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why NVAX maintains a \"Hold\" rating.",
    "url": "https://finnhub.io/api/news?id=33cde9f5159be311b9596bed99b110bf1d136b39fbec25a00518c5c34e92f54a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744360778,
      "headline": "Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer",
      "id": 133878610,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316007813/image_1316007813.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why NVAX maintains a \"Hold\" rating.",
      "url": "https://finnhub.io/api/news?id=33cde9f5159be311b9596bed99b110bf1d136b39fbec25a00518c5c34e92f54a"
    }
  }
]